Kornimate/medical-research-clean huggingface dataset:
an evaluation of a antimicrobial stewardship recommendation bundle for staphylococcus aureus bloodstream infections

Conditions: Bacterial Infections

Summary: in july 2020, a bundle (appendix c) was implemented at methodist dallas medical center where all patients with sab were reviewed by the antimicrobial stewardship pharmacist (monday - friday from 0700 to 1500), a note outlining optimal interventions was written in the electronic medical record (emr), and the recommendations were communicated to the primary team via secure messaging or telephone

evaluation of the staphylococcus aureus bloodstream infection(sab)bundle recommendations will allow for determination of whether this intervention is impactful and warrants the resources currently devoted to it.

Eligibility criteria:
inclusion criteria: * 18 years of age sab during hospital admission exclusion criteria: * patients with a history of a prior sab during the study period (only first occurrence included) * blood culture collected within 48hours of patient expiring or transitioning to hospice * patients discharged or left before culture results were available * patients transferred from an outside hospital
phosphate intake's effect on the skeletal system - pilot

Conditions: Healthy; Kidney Failure, Chronic

Summary: the purpose of this study is to determine the effects of different amounts of phosphorus in the diet on hormones that control phosphorus and bone health both in men who are healthy and in ones who have moderate kidney disease.

chronic kidney disease affects 11% of the us population; over half of those affected have skeletal manifestations of their renal disease. renal osteodystrophy is a complex disease, in which multiple mineral systems and related hormones play a role, including phosphate homeostasis. phosphate regulation primarily depends on renal handling of phosphate, which is partly controlled by parathyroid hormone and vitamin d. however, other mediators in this system clearly exist. recently, evidence has been accruing that one such factor may be fgf23, a protein produced by osteogenic cells. states of excess fgf23 are associated with marked phosphate wasting, hypophosphatemia, osteomalacia, and inappropriately low calcitriol. fgf23 levels are measurable in healthy humans and markedly elevated in patients who require hemodialysis, although its physiologic role in either state is unknown. some retrospective evidence suggests that fgf23 is affected by phosphate intake. we are performing a pilot study to gather preliminary data describing the response of fgf23 to changes in dietary phosphorus intake in healthy men and in men with moderate renal insufficiency. the specific aims of this pilot study are: 1) to examine the physiologic effects of alterations in dietary phosphorus on fgf23 in healthy subjects; 2) to examine the physiologic response of fgf23 to dietary phosphorus alterations in patients with moderate renal failure; 3) to assess whether serum levels of 1,25-dihydroxyvitamin d vary inversely with those of fgf23 when dietary phosphate is changed; 4) to determine the temporal pattern of calcitropic hormones and fgf23 in response to dietary phosphate changes; and 5) to determine the variability of the changes in serum fg 23 in response to dietary phosphate manipulations. the proposed research plan is a dietary intervention trial in which we will study the response of serum fgf23 levels to diets with varying phosphorus contents in healthy adults and adults with moderate renal insufficiency.

Eligibility criteria:
inclusion criteria: * healthy men 21-65 years old with creatinine clearance \> 70 ml/min/1.73 m2 as calculated using the equation derived from the modification of diet in renal disease (mdrd) study * men 21-65 years old with creatinine clearance between 30 and 59 ml/min/1.73 m2 as calculated using the equation derived from the mdrd study31 exclusion criteria: * medications affecting bone metabolism * abnormal liver or gi function * extreme electrolyte abnormalities * bmi \>30 kg/m2
internet cognitive behavior therapy (cbt) for obsessive compulsive disorder (ocd)

Conditions: Obsessive Compulsive Disorder

Summary: the main aim of this study is to test whether cognitive behavior therapy could be effective in treating obsessive compulsive disorder. here, the investigators test the in group effects of a 15 week long treatment delivered via the internet for residents in stockholm county.


Eligibility criteria:
inclusion criteria: * diagnosed with obsessive compulsive disorder according to the dsm criteria * be at least 18 years old * ybocs \>7 exclusion criteria: * other primary diagnosis * substance abuse, * psychosis, * bipolar disorder, * suicidal ideation, * adjusted pharmacological treatment the last two months * current psychological treatment for ocd, * been treated with cbt the last two years, * serious somatic disease, * y---bocs\>31 * hoarding as primary ocd subtype

Keywords: ocd cbt reducing ocd symptoms
microplasmin administered via the trellis-8 infusion system for treatment of acute iliofemoral dvt

Conditions: Deep Vein Thrombosis

Summary: a single centre, single-arm study to evaluate safety and efficacy of microplasmin administration via the trellis-8 infusion system in patients with acute iliofemoral dvt


Eligibility criteria:
inclusion criteria include: * patients with radiographically-confirmed acute proximal dvt exclusion criteria include: * isolated calf or popliteal vein dvt, based on duplex ultrasound * thrombus involving the inferior vena cava (ivc) * proximal (e.g. cranial) aspect of thrombus cannot be adequately assessed to level of the iliac veins or inferior vena cava, based on duplex ultrasound. * cannot traverse the target vessel segment with guidewire * symptomatic pulmonary embolism is present at time of presentation * documented history of prior dvt in target extremity * history of anticoagulants administered for \> 30 days for undocumented/ unclear reason (e.g. for reasons other than presence of mechanical cardiac valve, atrial fibrillation, etc.) * documented history of thrombophilic disorder, with diagnosis established via previous objective testing (e.g. familial screening for thrombophilia). * cannot receive standard secondary prevention pharmacotherapy \[i.e. heparin or lmwh and vitamin k antagonists (vka)\] due to contraindications to anticoagulation \[e.g. known bleeding diathesis, thrombocytopenia (platelets \< 100,000 mm3), heparin induced thrombocytopenia (hit), known allergy to heparin or warfarin\] * absolute contraindication to thrombolytic therapy * previous central nervous system haemorrhage * life expectancy less than 1 year, due to other comorbid condition. * previous intervention in target limb to address venous thrombus. * target limb has chronic venous insufficiency of c4 or greater severity * acute or chronic symptomatic musculoskeletal condition in target limb (e.g. trauma, fracture, severe arthritis). * documented patent foramen ovale or other right-to-left cardiac shunt. * absolute contraindication to contrast media or renal insufficiency (baseline creatinine \>2.0 mg/dl).

Keywords: acute iliofemoral deep vein thrombosis
immediate pain relieving effects of sinbaro-3 for low back pain

Conditions: Low Back Pain With Radiculopathy; Low Back Pain Without Radiculopathy; Herniated Intervertebral Disc

Summary: the purpose of this study is to investigate the immediate pain relieving effects of sinbaro-3 pharmaco-acupuncture in patients with low back pain admitted for inpatient care

60 patients with lbp with moderate to severe pain(nrs\>6) were randomly allocated to 2 groups. the experimental group was treated with sinbaro-3 pharmacoacupuncture and the control group was treated with hwangryun pharmacoacupuncture. all administrations were limited to 1 session, and comparisons of measurements were made before and after treatment. primary outcomes were measured using the vas scale. post-treatment follow-up will be performed to measure primary outcomes at 30 minutes, 2hours, 4hours, and 6 hours after treatment. before and after each measurement, the patients are asked to stand up and rotate their torso. at termination of the study, satisfaction levels of the patient's current status will also be collected.

Eligibility criteria:
inclusion criteria: * patients admitted to a korean medicine hospital for low back pain with or without radiculopathy * age between 18 and 69 * nrs score of \>6 on the day of the intervention * voluntary participation with written consent given to study consent form exclusion criteria: * diagnosis of serious disease(s) which are possible causes of back pain such as malignancy, vertebral fracture, spinal infection, inflammatory spondylitis, cauda equina compression, etc. * prior diagnosis of other chronic disease(s) which could affect effectiveness or interpretation of treatment results such as cardiovascular disease, diabetic neuropathy, fibromyalgia, rheumatoid arthritis, alzheimer's disease, epilepsy, etc. * progressive neurologic deficit(s) or concurrent severe neurological symptoms * unsuitable for or at risk of complications from acupuncture treatment such as patients with clotting disorders, severe diabetes with risk of infection, serious cardiovascular disease, or undergoing anticoagulant treatment, etc. * under prescription of corticosteroids, immuno-suppressant drugs, psychiatric medicine, or other medication considered unsuitable for subjects by the researcher * experience of gastroenteric complications after taking nsaids or currently undergoing treatment for digestive disorders * during pregnancy or suspected pregnancy * subjects considered unsuitable for clinical trial by the researcher

Keywords: low back pain pharmacoacupuncture sinbaro-3
development of a radiomics model with mr to predict the occurence of a infiltration of muscoskeletal tumor

Conditions: Soft Tissue Sarcoma (STS); Bone Cancer Tumor

Summary: the goal of this observational study is to evaluate the feasibility and clinical utility of radiomics to diagnose peri-lesion tumour infiltration of tumours in participants with a suspect of bone cancer tumor or soft tissue sarcoma (sts). the main questions it aims to answer are: * is radiomics able to identify the ratio of participants truly diagnosed as positive to all those who had positive test results? * is radiomics able to identify the likelihood that a participant who has a negative test result indeed does not have the disease? participants eligible for this study will get a mri as part of their regular medical care. the only difference is that their data will be recorded and anonymously analyzed.


Eligibility criteria:
inclusion criteria: * age over 18 * suspect of soft tissue sarcoma with a indication for surgical treatment * suspect of bone cancer tumor with a indication for surgical treatment * to give informed consent exclusion criteria: * simultaneous cancer or history of cancer in the last 5 years * acute or chronic serious conditions that could * contraindication to conduct a contrast-enhanced magnetic resonance imaging (mri) such as: * renal failure without dialysis * history of allergy to a paramagnetic contrast agent * claustrophobia * symptomatic epilepsy or history of epilepsy * cardiac pacemaker * infusion pump, prosthesis or any implant not compatible with mri * pregnancy
establishment of a tumor bank for tissue samples

Conditions: Ovarian Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasms of the Female Genitalia; Lung Neoplasms; Endocrine Gland Neoplasms

Summary: establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and malign tumors) and healthy people as controls. the tissue samples will be collected systematically together with the corresponding clinical data. the biological samples, the clinical date together with prospective experimental date constitute the entity of the tissue tumor bank. this tumor bank for tissue samples, together with our tumorbank for blood samples (nct01763125) combined constitute the entity "tumorbank".

recent progress in diagnosis and therapy of cancer diseases can be ascribed mainly to translational research. the relevance of "translational oncology" will only increase in the future -"from bench to bedside" - the swift implementation of new science research results in clinical studies in order to expedite progress in clinical cancer therapy for the benefit of the patient. its almost a matter of course in the medical science today to collect biological samples together with clinical information thereby creating the foundation for future excellent fundamental research. the aim of this tumor bank is to consist of biological samples (together with a blood bank - see nct01763125) and isolates of tumor patients and healthy people as controls. the biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank. the content of the tumor bank can provide essential material for current and future research (e.g. analyses of prognostic or predictive tumor markers; genetically analysis (polymorphism, mutation, hypermethylation; verification and characterisation of disseminated tumor cells).

Eligibility criteria:
inclusion criteria: * male/female * age 18 to 90 years max. * just one current known malignant disease or just one current inflammatory disease exclusion criteria: * inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage

Keywords: biobank fresh-frozen tissue
frenuloplasty for speech and myofunctional outcomes

Conditions: Ankyloglossia; Speech Delay; Dentofacial Abnormalities

Summary: children with ankyloglossia (tongue tie) can have abnormal tongue function, putting them at a disadvantage when it comes to speech and articulation. furthermore, abnormal tongue posture within the oral cavity increases the likelihood of myofunctional disorders.

the current body of literature surrounding ankyloglossia and speed delay is mixed. the literature base is riddled with retrospective reviews, poor descriptions of surgical intervention, and the lack of standardized grading schemes with respect to articulation. furthermore, the candidacy for intervention in these instances only involves children with anterior tongue tie. there is a complete lack of investigation surrounding the impact of posterior tongue tie on articulation. the other area that has inadequately been studied is the impact ankyloglossia has on myofunctional outcomes. there are data now that demonstrate how ankyloglossia is correlated with a vaulted palate and has long term orthodontic consequences. this study aims to demonstrate how release of posterior tongue tie improves lingual strength and posture.

Eligibility criteria:
inclusion criteria: * children ages 5-12 with posterior tongue tie who are undergoing treatment just for ankyloglossia * children must already be working with an slp who has done a speech and myofunctional evaluation exclusion criteria: * children undergoing other procedures at the same time as the frenuloplasty (tonsillectomy, adenoidectomy, etc) * significant medical comorbidities (cardiovascular, neurological, etc) * anterior tongue tie or lip tie * previous lingual surgery

Keywords: ankyloglossia speech delay myofunctional therapy dentofacial abnormalities
the effects of dexmedetomidine to postoperative awakening and extubation-related changes in blood pressure

Conditions: Hypertension

Summary: the postoperative removal of intubation tube induces a noticeable sympathic response and increase of blood pressure. the risk of complications is especially elevated with the patients having cardiac surgery. though sedation inhibits the sympathetic responses to extubation, according to the current protocol the propofol infusion has to be discontinued well before extubation because of its inhibitory effects on breathing centers. dexmedetomidine is relatively new anesthesia drug. dexmedetomidine is unique in its characteristic that it does not have the paralyzing effect on breathing. the aim of our study is to work out whether dexmedetomidine-extended propofol sedation over the extubation diminishes the aforementioned harmful effects of the extubation procedure. study design is prospective double-blinded randomized study. the investigators compare two groups of 25 patients (total 50), who are of 60-90 years of age and are having either aortic valve surgery or the mentioned accompanied with cardiopulmonary bypass operation. the first group receives dexmedetomidine infusion and the other receives placebo infusion after the end of propofol infusion. the specific goal of the study is to figure what haemodynamic - mostly blood pressure related - changes can be observed when the postoperatively cut propofol infusion is continued with dexmedetomidine over the extubation procedure. our hypothesis is that by using dexmedetomidine supplemented sedation the normally notifiable peak in blood pressure may be avoided. the study will be carried out completely in cardiac icu in tampere university hospital.


Eligibility criteria:
inclusion criteria: * patient has to be scheduled for aortic valve surgery or previous and coronary artery bypass * patient has to be 60 to 90 years of age exclusion criteria: * if a patient is unable to give informed concent to participate the study * if a patient is allergic or otherwise hypersensitive to the drug used in the study * if the patient has either insufficient kidney or insufficient liver function

Keywords: dexmedetomidine postoperative period airway extubation systolic pressure
everolimus in selected patients with metastatic melanoma: efficacy and safety study

Conditions: Melanoma; TOR Serine-Threonine Kinases; Neoplasm Metastasis

Summary: this is a single-armed, open-labeled and single-centered study of everolimus in selective patients with metastatic melanoma for evaluation of the efficacy and safety. the study objective is to evaluate efficacy profile of everolimus. the patients who comply with the inclusion and exclusion criteria will be enrolled. the estimated recruiting duration is 18 months. everolimus will be given in the dose of 10 mg orally each day at lease 6 months unless disease progression or intolerance. the follow-up is till death(at least 1 year).


Eligibility criteria:
inclusion criteria: clinical diagnosis of metastases melanoma. must have evidence of mutations(kinase domain) of mtor . must be ecog performance status 0,1, or 2 . must be estimated life expectancy of 3 months or greater. must be age 18 years or older, male or female. must have at least one measurable site of disease as defined by at least 1 cm in greatest dimension. adequate organ function. must be willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. exclusion criteria: prior systemic therapy for metastatic disease within 4 weeks. second malignancy within the last 5 years. severe and/or uncontrolled medical disease. received rad001 or other mtor inhibitors previously . hypersensitivity to everolimus current treatment on another clinical trial. pregnancy or breastfeeding.

Keywords: melanoma tor serine-threonine kinases
time-restricted eating in survivors trial

Conditions: Cancer, Breast

Summary: breast cancer survivors aged 60+ and with overweight/obesity who had completed chemotherapy 1-6 years earlier completed 8 weeks of 12-8 pm weekday-only time-restricted eating. the intervention was delivered by a registered dietitian call, twice-daily automated text messages asking about eating start/stop times, and three support phone calls.


Eligibility criteria:
inclusion criteria: * history of early-stage (i-iii) breast cancer * completed anthracycline-based chemotherapy 1-6 years earlier * aged ≥60 years * had a body mass index (bmi) \>25 kg/m2 exclusion criteria: * taking lipid, glucose, or weight-lowering medications * contraindications to maximal exercise testing or research mri * unstable thyroid disorder * self-reported history of an eating disorder * self-reported diagnosis of type 1 or 2 diabetes * weight loss of ≥15 lbs in previous 3 months * working night shifts * could not provide consent in english
genetic predictors of outcome in hcm patients

Conditions: Hypertrophic Cardiomyopathy

Summary: this is a retrospective review of the data available on patients and their family members with hcm and prospective follow-up of this cohort for clinical outcome and diagnostic studies. genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-ar polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as lvh in patients with hcm and whether these polymorphisms influence the clinical course and outcome in patients with hcm. for that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with hcm that have regular follow up and test them for beta-ar polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with hcm.

this is a retrospective review of the data available on patients and their family members with hcm and prospective follow-up of this cohort for clinical outcome and diagnostic studies. genetic samples are being examined in this cohort to determine whether certain to determine whether certain beta-ar polymorphisms as well as other common genetic polymorphisms are associated with different morphological features, such as lvh in patients with hcm and whether these polymorphisms influence the clinical course and outcome in patients with hcm. for that purpose, we will build a database with clinical information including serial echocardiographic measurements for patients with hcm that have regular follow up and test them for beta-ar polymorphisms as well as other common genetic polymorphisms and other known cardiac-related polymorphisms that can potentially contribute to the morphologic differences seen in patients with hcm.

Eligibility criteria:
inclusion criteria: * 18+ years of age * diagnosed with hcm defined by the presence of left ventricular hypertrophy with minimal wall thickness \>/= 15mm without the presence of hypertension or systemic disease that can account for the degree of hypertrophy. exclusion criteria: * hypertension present prior to the diagnosis of hcm * aortic stenosis with aortic valve area \< 1cm2 * known systemic disease that can cause lvh, such as infiltrative diseases * able and willing to provide informed consent

Keywords: genetic testing